Back to results
US 12,624,091 B2Granted
HIV/HCV cross-reactive antibodies and uses thereof
AssigneeVanderbilt University
InventorsKelsey Pilewski, Ivelin Stefanov Georgiev
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to antibodies and uses thereof for treating an HIV infection, an HCV infection, or an HIV/HCV co-infection.
Claims19
A recombinant antibody for binding both Human Immunodeficiency virus (HIV) and Hepatitis C virus (HCV), said antibody comprising a light chain variable region (VL) that comprises a light chain complementarity determining region (CDRL) 1, CDRL2, and CDRL3 and a heavy chain variable region (VH) that comprises a heavy chain complementarity determining region (CDRH) 1, CDRH2, and CDRH3, wherein:
- (i) CDRH1 is SEQ ID NO:
- 13107, CDRH2 is SEQ ID NO:
- 13113, CDRH3 is SEQ ID NO:
- 110 or 1822, CDRL1 is SEQ ID NO:
- 13125, CDRL2 is SEQ ID NO:
- 13131, and CDRL3 is SEQ ID NO:
- 101 or 1888;
- (ii) CDRH1 is SEQ ID NO:
- 13106, CDRH2 is SEQ ID NO:
- 13112, CDRH3 is SEQ ID NO:
- 104 or 1821, CDRL1 is SEQ ID NO:
- 13124, CDRL2 is SEQ ID NO:
- 13130, and CDRL3 is SEQ ID NO:
- 88 or 1887;
- (iii) CDRH1 is SEQ ID NO:
- 13102, CDRH2 is SEQ ID NO:
- 13108, CDRH3 is SEQ ID NO:
- 1817, CDRL1 is SEQ ID NO:
- 13120, CDRL2 is SEQ ID NO:
- 13126, and CDRL3 is SEQ ID NO:
- 13 or 1883;
- (iv) CDRH1 is SEQ ID NO:
- 13103, CDRH2 is SEQ ID NO:
- 13109, CDRH3 is SEQ ID NO:
- 1818, CDRL1 is SEQ ID NO:
- 13121, CDRL2 is SEQ ID NO:
- 13127, and CDRL3 is SEQ ID NO:
- 25 or 1884;
- (v) CDRH1 is SEQ ID NO:
- 13104, CDRH2 is SEQ ID NO:
- 13110, CDRH3 is SEQ ID NO:
- 1819, CDRL1 is SEQ ID NO:
- 13122, CDRL2 is SEQ ID NO:
- 13128, and CDRL3 is SEQ ID NO:
- 39 or 1885;
- or
- (vi) CDRH1 is SEQ ID NO:
- 13105, CDRH2 is SEQ ID NO:
- 13111, CDRH3 is SEQ ID NO:
- 1820, CDRL1 is SEQ ID NO:
- 13123, CDRL2 is SEQ ID NO:
- 13129, and CDRL3 is SEQ ID NO:
- 49 or 1886.
40 more elements
Dependencies are inferred from the claim text.